Results 131 to 140 of about 174,156 (175)
Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial. [PDF]
Liu Y+13 more
europepmc +1 more source
A Case Series and Literature Review on Zanubrutinib Therapy for the Treatment of Relapsed/Refractory Immune Thrombocytopenia. [PDF]
Ding B+7 more
europepmc +1 more source
SummaryX‐linked agammaglobulinaemia (XLA) is an immunodeficiency caused by Bruton tyrosine kinase (BTK) gene mutations. The disease is characterized by recurrent bacterial infections and profound hypogammaglobulinemia with marked reduction or lack of mature B‐cells in the peripheral blood.
Lee, TL+7 more
semanticscholar +7 more sources
Orphan designation: Agammaglobulinaemia tyrosine kinase, Treatment of pemphigus
semanticscholar +5 more sources
Lenalidomide/rituximab/agammaglobulinaemia-tyrosine-kinase-inhibitors
semanticscholar +3 more sources
Agammaglobulinaemia-tyrosine-kinase-inhibitors/cyclophosphamide/fludarabine
semanticscholar +3 more sources